Procept Biorobotics Corp Stock Price, News & Analysis

PROCEPT BioRobotics (Nasdaq: PRCT) reported third-quarter 2025 results with Q3 revenue of $83.3M, up 43% year‑over‑year, and U.S. handpiece and consumables revenue of $44.4M (+50% YoY). The U.S. installed base reached 653 systems after adding 58 systems in the quarter. Gross margin expanded to 65%. Net loss was $21.4M and adjusted EBITDA loss improved to $7.4M in Q3. Cash and equivalents totaled $297.3M as of September 30, 2025. The company reiterated 2025 revenue guidance of about $325.5M and issued 2026 revenue guidance of $410–$430M (growth 26%–32%).

PROCEPT BioRobotics (Nasdaq: PRCT) announced it will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025.

Management will host a conference call the same day at 4:30 p.m. Eastern Time. Investors can listen via webcast or dial-in registration. Live and archived audio will be available in the company’s Investors section; each webcast will be replayable for at least 90 days.

Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.

PROCEPT BioRobotics (Nasdaq: PRCT) reported strong Q2 2025 financial results with total revenue of $79.2 million, up 48% year-over-year. The company's U.S. revenue grew 46% to $69.6 million, driven by system sales and increased handpiece revenue. International revenue surged 69% to $9.6 million.

Key highlights include 51 new U.S. robotic system sales and an expanded U.S. install base of 595 systems. Gross margin improved to 65% from 59% year-over-year. The company increased its 2025 revenue guidance to $325.5 million, representing 45% growth. Additionally, PROCEPT announced the appointment of Larry Wood as CEO, effective September 2, 2025.

PROCEPT BioRobotics (Nasdaq: PRCT) announced a significant leadership transition as CEO Dr. Reza Zadno plans to retire, with Larry L. Wood appointed as the new President and CEO effective September 2, 2025. Under Dr. Zadno's leadership since 2020, the company achieved notable milestones including successful commercialization of Aquablation® therapy, completion of its 2021 IPO, and initiation of prostate cancer clinical trials.

Mr. Wood joins from Edwards Lifesciences, bringing over 40 years of medical technology experience. The company also pre-announced strong Q2 2025 revenue of approximately $79.2 million, representing 48% annual growth. During Dr. Zadno's tenure, global Aquablation procedures grew from hundreds to nearly 100,000, with the company raising over $600M in capital.

PROCEPT BioRobotics (Nasdaq: PRCT) announced a significant milestone in its WATER IV Prostate Cancer Trial, with three successful prostate cancer procedures completed at an Ambulatory Surgery Center (ASC) using Aquablation® therapy. The procedures were performed by Dr. Rahul Mehan in Scottsdale, Arizona.

The FDA-approved IDE clinical study aims to compare Aquablation® therapy with radical prostatectomy for treating localized prostate cancer (Grade Group 1 to 3). Aquablation therapy utilizes a robotically-controlled waterjet for targeted prostate tissue removal, while radical prostatectomy involves complete prostate removal.

This milestone demonstrates the potential for treating early-stage prostate cancer in an ASC setting, suggesting a more scalable and cost-effective care model for prostate cancer treatment.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.

The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access the call through a webcast link or dial-in registration for sell-side analysts. The webcast recording will be available for at least 90 days on the company's investor relations website.

PROCEPT BioRobotics (Nasdaq: PRCT) announced that its Aquablation therapy has been assigned a Category I CPT code (52XX1) effective January 1, 2026, replacing the current Category III code 0421T. The 2026 Medicare Proposed Physician Fee Schedule assigns 16.14 total RVUs to Aquablation therapy, translating to approximately $540 in national average payment, slightly higher than TURP's 15.82 RVUs ($529).

This milestone recognition reflects Aquablation therapy's clinical value and widespread adoption in BPH surgical treatment. The proposed payment rates are subject to a public comment period ending September 2025, with the Final Rule expected in November 2025.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in four major investor conferences during May and June 2025.

The conference schedule includes:

• Bank of America Health Care Conference in Las Vegas - Fireside Chat on May 14
• William Blair Growth Stock Conference in Chicago - Presentation on June 4
• Jefferies Global Healthcare Conference in New York City - Fireside Chat on June 5
• Truist Med-Tech Conference in Boston - Fireside Chat on June 17

All events will be accessible via live webcast through the company's investor relations website, with recordings available for replay up to 90 days after each event.